Antipneumococcal activities of gemifloxacin compared to those of nine other agents

被引:78
作者
Davies, TA
Kelly, LM
Pankuch, GA
Credito, KL
Jacobs, MR
Appelbaum, PC
机构
[1] Penn State Univ, Milton S Hershey Med Ctr, Dept Pathol & Clin Microbiol, Hershey, PA 17033 USA
[2] Case Western Reserve Univ, Dept Pathol & Clin Microbiol, Cleveland, OH 44106 USA
关键词
D O I
10.1128/AAC.44.2.304-310.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The activities of gemifloxacin compared to those of nine other agents was tested against a range of penicillin-susceptible and -resistant pneumococci by agar dilution, microdilution, time-kill, and post-antibiotic effect (PAE) methods. Against 64 penicillin-susceptible, 68 penicillin-intermediate, and 75 penicillin-resistant pneumococci (all quinolone susceptible), agar dilution MIC(50)s (MICs at which 50% of isolates are inhibited)/MIC(90)s (in micrograms per milliliter) were as follows: gemifloxacin, 0.03/0.06; ciprofloxacin, 1.0/4.0; levofloxacin, 1.0/2.0; sparfloxacin, 0.5/1.0; grepafloxacin, 0.125/0.5; trovafloxacin, 0.125/0.25; amoxicillin, 0.016/0.06 (penicillin-susceptible isolates), 0.125/1.0 (penicillin-intermediate isolates), and 2.0/4.0 (penicillin-resistant isolates); cefuroxime, 0.03/0.25 (penicillin-susceptible isolates), 0.5/2.0 (penicillin-intermediate isolates), and 8.0/16.0 (penicillin-resistant isolates); azithromycin, 0.125/0.5 (penicillin-susceptible isolates), 0.125/>128.0 (penicillin-intermediate isolates), and 4.0/>128.0 (penicillin-resistant isolates); and clarithromycin, 0.03/0.06 (penicillin-susceptible isolates), 0.03/32.0 (penicillin-intermediate isolates), and 2.0/>128.0 (penicillin-resistant isolates). Against 28 strains with ciprofloxacin MICs of greater than or equal to 8 mu g/ml, gemifloxacin had the lowest MICs (0.03 to 1.0 mu g/ml; MIC90, 0.5 mu g/ml), compared with MICs ranging between 0.25 and >32.0 mu g/ml (MIC(90)s of 4.0 to >32.0 mu g/mL) for other quinolones. Resistance in these 28 strains was associated with mutations in parC, gyrA, parE, and/or gyrB or efflux, with some strains having multiple resistance mechanisms. For 12 penicillin-susceptible and -reslstant pneumococcal strains (2 quinolone resistant), time-kill results showed that levofloxacin at the MIC, gemifloxacin and sparfloxacin at two times the MIC, and ciprofloxacin, grepafloxacin, and trovafloxacin at four times the MIC were bactericidal for all strains after 24 h. Gemifloxacin was uniformly bactericidal after 23 h at less than or equal to 0.5 mu g/ml. Various degrees of 90 and 99% killing by all quinolones were detected after 3 h, Gemifloxacin and trovafloxacin were both bactericidal at two times the MIC for the two quinolone-resistant pneumococci, Amoxicillin at two times the MIC and cefuroxime at four times the MIC were uniformly bactericidal after 23 h, with some degree of killing at earlier time points. Macrolides gave slower killing against the seven susceptible strains tested, with 99.9% killing of all strains at two to four times the MIC after 24 h, PAEs for five quinolone-susceptible strains were similar (0.3 to 3.0 h) for all quinolones, and significant quinolone PAEs were found for the quinolone-resistant strain.
引用
收藏
页码:304 / 310
页数:7
相关论文
共 29 条
  • [1] ANTIMICROBIAL RESISTANCE IN STREPTOCOCCUS-PNEUMONIAE - AN OVERVIEW
    APPELBAUM, PC
    [J]. CLINICAL INFECTIOUS DISEASES, 1992, 15 (01) : 77 - 83
  • [2] PENICILLIN-RESISTANT STREPTOCOCCUS-PNEUMONIAE IN ACUTE OTITIS-MEDIA - RISK-FACTORS, SUSCEPTIBILITY PATTERNS AND ANTIMICROBIAL MANAGEMENT
    BLOCK, SL
    HARRISON, CJ
    HEDRICK, JA
    TYLER, RD
    SMITH, RA
    KEEGAN, E
    CHARTRAND, SA
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1995, 14 (09) : 751 - 759
  • [3] EMERGENCE OF DRUG-RESISTANT PNEUMOCOCCAL INFECTIONS IN THE UNITED-STATES
    BREIMAN, RF
    BUTLER, JC
    TENOVER, FC
    ELLIOTT, JA
    FACKLAM, RR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23): : 1831 - 1835
  • [4] Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae
    Brenwald, NP
    Gill, MJ
    Wise, R
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) : 2032 - 2035
  • [5] Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone
    Cormican, MG
    Jones, RN
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) : 204 - 211
  • [6] Craig WA, 1996, ANTIBIOTICS LAB MED, P296
  • [7] In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae
    Davies, TA
    Pankuch, GA
    Dewasse, BE
    Jacobs, MR
    Appelbaum, PC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) : 1177 - 1182
  • [8] Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study
    Doern, GV
    Brueggemann, A
    Holley, HP
    Rauch, AM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) : 1208 - 1213
  • [9] MANAGEMENT OF PENICILLIN-RESISTANT PNEUMOCOCCAL INFECTIONS
    FRIEDLAND, IR
    ISTRE, GR
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1992, 11 (06) : 433 - 435
  • [10] FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607